These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

523 related items for PubMed ID: 28748389

  • 41. Bisphosphonates and atypical femoral fractures: Is the location of the fracture associated with the time of consolidation?
    Llano L, Barla J, Taype D, Garcia Barreiro G, Sancineto C, Carabelli G.
    Injury; 2023 Nov; 54 Suppl 6():110730. PubMed ID: 38143116
    [Abstract] [Full Text] [Related]

  • 42. Bone Formation Parameters of the Biopsied Ilium Differ between Subtrochanteric and Diaphyseal Atypical Femoral Fractures in Bisphosphonate-Treated Patients.
    Kondo N, Fukuhara T, Watanabe Y, Miyasaka D, Yamamoto N, Sato H, Wada Y, Nakatsue T, Fujisawa J, Sakuma M, Imai N, Yoda T, Narita I, Endo N.
    Tohoku J Exp Med; 2017 Dec; 243(4):247-254. PubMed ID: 29212985
    [Abstract] [Full Text] [Related]

  • 43. Gene Network of Susceptibility to Atypical Femoral Fractures Related to Bisphosphonate Treatment.
    Garcia-Giralt N, Roca-Ayats N, Abril JF, Martinez-Gil N, Ovejero D, Castañeda S, Nogues X, Grinberg D, Balcells S, Rabionet R.
    Genes (Basel); 2022 Jan 14; 13(1):. PubMed ID: 35052486
    [Abstract] [Full Text] [Related]

  • 44. A proposal for an atypical femur fracture treatment and prevention clinical practice guideline.
    Dell R, Greene D.
    Osteoporos Int; 2018 Jun 14; 29(6):1277-1283. PubMed ID: 29675745
    [Abstract] [Full Text] [Related]

  • 45. Natural history of incomplete atypical femoral fractures in patients after a prolonged and variable course of bisphosphonate therapy-a long-term radiological follow-up.
    Png MA, Mohan PC, Koh JSB, Howe CY, Howe TS.
    Osteoporos Int; 2019 Dec 14; 30(12):2417-2428. PubMed ID: 31435684
    [Abstract] [Full Text] [Related]

  • 46. Medical Management of Patients After Atypical Femur Fractures: a Systematic Review and Recommendations From the European Calcified Tissue Society.
    van de Laarschot DM, McKenna MJ, Abrahamsen B, Langdahl B, Cohen-Solal M, Guañabens N, Eastell R, Ralston SH, Zillikens MC.
    J Clin Endocrinol Metab; 2020 May 01; 105(5):1682-99. PubMed ID: 31867670
    [Abstract] [Full Text] [Related]

  • 47. Can long-term bisphosphonate use causes low-energy fractures? A case report.
    Dandinoğlu T, Akarsu S, Karadeniz M, Tekin L, Arıbal S, Kıralp MZ.
    Osteoporos Int; 2014 Feb 01; 25(2):773-6. PubMed ID: 23824297
    [Abstract] [Full Text] [Related]

  • 48. Factors affecting fracture location in atypical femoral fractures: A cross-sectional study with 147 patients.
    Kim JW, Kim JJ, Byun YS, Shon OJ, Oh HK, Park KC, Kim JW, Oh CW.
    Injury; 2017 Jul 01; 48(7):1570-1574. PubMed ID: 28571705
    [Abstract] [Full Text] [Related]

  • 49. Atypical periprosthetic femoral fracture associated with long-term bisphosphonate therapy.
    Dózsai D, Ecseri T, Csonka I, Gárgyán I, Doró P, Csonka Á.
    J Orthop Surg Res; 2020 Sep 15; 15(1):414. PubMed ID: 32933566
    [Abstract] [Full Text] [Related]

  • 50. Comparison of bone turnover suppression in atypical femoral fractures and osteoporotic hip fractures.
    Ahn J, Kim CH, Kim JW.
    Sci Rep; 2024 Aug 28; 14(1):19974. PubMed ID: 39198602
    [Abstract] [Full Text] [Related]

  • 51. Bone turnover markers and the factors associated with atypical femur fractures among Japanese patients.
    Iizuka Y, Iizuka H, Kaneko T, Mieda T, Takechi R, Suzuki H, Sorimachi Y, Suto T, Tachibana M, Yoneyama T, Omodaka T, Hashimoto S, Hamano N, Sakane H, Shimoyama D, Kohama I, Ohshima A, Nozaki T, Kamiyama M, Moteki T, Ohshima A, Takamine S, Honda A, Ueno A, Tajika T, Okamura K, Warita T, Yonemoto Y, Shitara H, Ohsawa T, Takagishi K.
    Injury; 2016 Nov 28; 47(11):2484-2489. PubMed ID: 27670281
    [Abstract] [Full Text] [Related]

  • 52. Radiological criteria for atypical features of femur fractures: what we can learn when applied in a clinical study setting.
    LeBlanc ES, Rosales AG, Genant HK, Dell RM, Friess DM, Boardman DL, Santora AC, Bauer DC, de Papp AE, Black DM, Orwoll ES.
    Osteoporos Int; 2019 Jun 28; 30(6):1287-1295. PubMed ID: 30809724
    [Abstract] [Full Text] [Related]

  • 53. Radiographic Changes and Fracture in Patients Having Received Bisphosphonate Therapy for ≥ 5 Years at a Single Institution.
    Ernat J, Song D, Fazio M, Lindell K, Orchowski J.
    Mil Med; 2015 Dec 28; 180(12):1214-8. PubMed ID: 26633664
    [Abstract] [Full Text] [Related]

  • 54. Duration-Dependent Increase of Human Bone Matrix Mineralization in Long-Term Bisphosphonate Users with Atypical Femur Fracture.
    Farlay D, Rizzo S, Ste-Marie LG, Michou L, Morin SN, Qiu S, Chavassieux P, Chapurlat RD, Rao SD, Brown JP, Boivin G.
    J Bone Miner Res; 2021 Jun 28; 36(6):1031-1041. PubMed ID: 33434290
    [Abstract] [Full Text] [Related]

  • 55. Cumulative incidence of femoral localized periosteal thickening (beaking) preceding atypical femoral fractures in patients with rheumatoid arthritis.
    Sato H, Takai C, Kondo N, Kurosawa Y, Hasegawa E, Wakamatsu A, Kobayashi D, Nakatsue T, Abe A, Ito S, Ishikawa H, Kazama JJ, Kuroda T, Suzuki Y, Endo N, Narita I.
    Osteoporos Int; 2021 Feb 28; 32(2):363-375. PubMed ID: 32885317
    [Abstract] [Full Text] [Related]

  • 56. Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries.
    Wang Z, Ward MM, Chan L, Bhattacharyya T.
    Osteoporos Int; 2014 Aug 28; 25(8):2109-16. PubMed ID: 24846316
    [Abstract] [Full Text] [Related]

  • 57. Medication management after intramedullary nailing of atypical fractures.
    Feron JM, Cambon-Binder A.
    Injury; 2017 Jun 28; 48 Suppl 1():S15-S17. PubMed ID: 28456365
    [Abstract] [Full Text] [Related]

  • 58. Atypical femoral fractures shortly after osteonecrosis of the jaw in a postmenopausal woman taking alendronate for osteoporosis.
    Chiu WY, Lee JJ, Tsai KS.
    J Clin Endocrinol Metab; 2013 Apr 28; 98(4):E723-6. PubMed ID: 23471975
    [Abstract] [Full Text] [Related]

  • 59. Recurrence of bilateral atypical femoral fractures associated with the sequential use of teriparatide and denosumab: a case report.
    Ramchand SK, Chiang CY, Zebaze RM, Seeman E.
    Osteoporos Int; 2016 Feb 28; 27(2):821-5. PubMed ID: 26458389
    [Abstract] [Full Text] [Related]

  • 60. Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates.
    Sánchez A, Blanco R.
    Osteoporos Int; 2017 Mar 28; 28(3):1145-1147. PubMed ID: 27866217
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.